[
  {
    "ts": null,
    "headline": "Gilead Sciences Inc. stock outperforms competitors on strong trading day",
    "summary": "Gilead Sciences Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=889ab5e6d3f2df03f4271943e646c2b5f403f6df1fc5fe852ef1e2ccd66b9e05",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733416920,
      "headline": "Gilead Sciences Inc. stock outperforms competitors on strong trading day",
      "id": 131877465,
      "image": "",
      "related": "GILD",
      "source": "MarketWatch",
      "summary": "Gilead Sciences Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=889ab5e6d3f2df03f4271943e646c2b5f403f6df1fc5fe852ef1e2ccd66b9e05"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences Is Turning Itself Around. Why Its Stock Can Keep Rallying.",
    "summary": "For years,  Gilead Sciences  was dead money for shareholders.  Shares of the drugmaker, with a market capitalization of just over $117 billion, fell from roughly $89 in the middle of 2016 through June.  Earnings per share shrank as the company struggled to find opportunities beyond sales of Biktarvy, the HIV drug that accounts for nearly half of annual sales.",
    "url": "https://finnhub.io/api/news?id=36f999f4f985c3c8a0e6c9e7167072f05d22ee3285dfd8ec57edbb2b1cc83207",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733389200,
      "headline": "Gilead Sciences Is Turning Itself Around. Why Its Stock Can Keep Rallying.",
      "id": 131795094,
      "image": "",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "For years,  Gilead Sciences  was dead money for shareholders.  Shares of the drugmaker, with a market capitalization of just over $117 billion, fell from roughly $89 in the middle of 2016 through June.  Earnings per share shrank as the company struggled to find opportunities beyond sales of Biktarvy, the HIV drug that accounts for nearly half of annual sales.",
      "url": "https://finnhub.io/api/news?id=36f999f4f985c3c8a0e6c9e7167072f05d22ee3285dfd8ec57edbb2b1cc83207"
    }
  }
]